country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-186078

Copy Link Print Information

SRA-36

SRA-36 is a CLC-K chloride channel inhibitor with selectivity over CLC-5 and CLC-1 chloride channels. SRA-36 blocks CLC-Ka currents with an IC₅₀ of 6.6 μM and a K_d of 3.8 μM. SRA-36 blocks chloride currents mediated by targeted channels, and inhibits currents from hypertension-associated CLC-Ka^A447T and CLC-Ka^Y315F polymorphisms. SRA-36 can be used for the research of hypertension.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Formule: C₂₂H₁₆O₃
Masse moléculaire:328.36

Stockage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (270 KB)

SRA-36 Chemical Structure

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- In Vitro
Chemical Information
Pureté et documentation
Références
Calculators
Help & FAQs
Classifications
Bioz

Activité biologique

Description

In Vitro

SRA-36 potently inhibits chloride currents from wild-type CLC-Ka channels heterologously expressed in HEK293 cells, with an IC₅₀ of 6.6 μM^[1].
SRA-36 potently inhibits chloride currents from wild-type CLC-Ka channels heterologously expressed in MDCK cells, with an apparent K_D of 3.8 μM^[1].
SRA-36 potently inhibits chloride currents from CLC-Kb and rat CLC-K1 channels heterologously expressed in HEK293 cells, reducing currents by ~90% at 50 μM^[1].
SRA-36 (5 μM) does not inhibit chloride currents from CLC-5 or CLC-1 channels heterologously expressed in HEK293 cells at a concentration of 5 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

Masse moléculaire 328.36
Formule C₂₂H₁₆O₃
SMILES

OC(C1=C(C2=CC(CC3=CC=CC=C3)=CC=C2O1)C4=CC=CC=C4)=O
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

Please store the product under the recommended conditions in the Certificate of Analysis.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (270 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Liantonio A, et al. Kidney CLC-K chloride channels inhibitors: structure-based studies and efficacy in hypertension and associated CLC-K polymorphisms. J Hypertens. 2016;34(5):981-992. [Content Brief]

Calculators

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

100 mg

Obtenir un devis En stock